Oculis Holding AG (OCSAW)
| Market Cap | 456.20M -51.4% |
| Revenue (ttm) | 1.12M +49.9% |
| Net Income | -96.57M |
| EPS | -1.62 |
| Shares Out | 60.79M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 1.990 |
| Previous Close | 1.950 |
| Day's Range | 1.990 - 1.990 |
| 52-Week Range | 1.690 - 22.635 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About OCSAW
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological da... [Read more]
News
Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses
FDA IND clearance opens a new era for Oculis in neurology, initiating clinical development in acute MS relapses by building directly upon the positive Phase 2 ACUITY trial and ongoing PIONEER program ...
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
ZUG, Switzerland, Nov. 13, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.
Oculis Holding AG Transcript: Stifel 2026 Healthcare Conference 2026
Privosegtor’s Phase II results support a Phase III neuro-ophthalmology program, with PIONEER-1 enrollment underway and topline potentially around year-end 2027. Licaminlimab’s TNFR1-enriched dry-eye readout is expected in December 2026 or January 2027.
Oculis Holding AG Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
PREDICT-1 results are expected within weeks, while PIONEER-1 advances toward year-end site goals. Management outlined biomarker-led dry-eye development and a privosegtor program spanning optic neuritis and acute MS relapse.
Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline
ZUG, Switzerland, November 9, 2026 -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations in neuro-ophthalmology and ophthalmo...
Oculis price target lowered to $40 from $45 at Guggenheim
Guggenheim lowered the firm’s price target on Oculis (OCS) to $40 from $45 and keeps a Buy rating on the shares.
Oculis reports Q3 EPS (30c), consensus (39c)
Riad Sherif, M.D., Chief Executive Officer of Oculis (OCS), stated: “The third quarter marked notable progress across our late-stage pipeline, advancing us towards several major value-driving mileston...
Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts
ZUG, Switzerland, November 3, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significa...
Oculis Holding AG Earnings release: Q3 2026
Oculis Holding AG released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation
Björn Tackenberg, M.D. Ph.D. FEAN FAAN, Professor of Neurology, will lead Oculis' global integrated scientific strategy supporting the advancement of Privosegtor and its expansion into new therapeutic...
Oculis to Feature Privosegtor's Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit
Positive Phase 2 ACUITY trial findings support Privosegtor's potential to deliver a first-in-class neuroprotective treatment for patients with optic neuritis and beyond
Oculis reports Phase 2 data supporting Privosegtor in optic neuritis
Oculis (OCS) announced new translational biomarker data from the Phase 2 ACUITY trial of Privosegtor in patients with optic neuritis. Increases in plasma neurofilament light chain and plasma glial fib...
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor's Neuroprotective Potential in Optic Neuritis
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor's Neuroprotective Potential in Optic Neuritis
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo
Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
Presentation highlights new translational data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation
Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki
Markviss innritun sjúklinga með auknar líkur á meðferðarsvörun: 2/3 af þeim 176 sjúklingum sem innritaðir voru bera þann TNFR1-erfðabreytileika sem tengdur hefur verið aukinni klínískri svörun í fasa ...
Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease
High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials
Oculis Holding AG Slides: Study presentation
Oculis Holding AG has posted slides in relation to its latest quarterly earnings report, which was published on October 12, 2026.
Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day
Licaminlimab genotype-based precision medicine approach for TNFR1-mediated dry eye disease in PREDICT-1 registrational symptoms trial on track for topline readout around year-end
Oculis Joins the National Multiple Sclerosis Society's Campaign to End MS
Oculis and the National Multiple Sclerosis Society's campaign share a common goal to accelerate breakthroughs in MS research and improve patients' quality of life
Oculis Announces Resignation of Lionel Carnot from Board of Directors
ZUG, Switzerland, September 30, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address signi...
Oculis Holding AG Slides: FY 2026
Oculis Holding AG has posted slides in relation to its FY 2026 quarterly earnings report, which was published on September 30, 2026.
Oculis price target raised to $39 from $26 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen raised the firm’s price target on Oculis (OCS) to $39 from $26 and keeps a Buy rating on the shares. The company’s PREDICT-1 trial of…
Oculis Holding AG Transcript: 2026 Global Healthcare Conference
Two late-stage programs are advancing: Licaminlimab for TNFR1 dry eye, using a precision medicine approach with a phase III readout expected late 2026/early 2027, and Privosegtor for acute optic neuritis, now in global phase III after strong phase II results. Expansion into MS relapses and NAION is planned, with robust financing supporting all clinical activities.
Oculis Holding AG Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Precision medicine is central to ongoing trials, with TNFR1 biomarker enrichment guiding patient selection and regulatory strategy. Key programs are fully funded through 2029, and recent asset acquisitions have improved cost structure and flexibility.